[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338938-105":59,"doc-detail-338938-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advances-in-dna-damage-response-inhibitors-in-colorectal-cancer-therapy","Advances in DNA damage response inhibitors in colorectal cancer therapy","","One potential cause of cancer is genomic instability driven by accumulated DNA damage in normal cells, while radiotherapy and cytotoxic drugs aim to damage cancer-cell DNA but also harm normal tissue. Although molecular targeted therapy and immunotherapy have advanced for colorectal cancer (CRC), many patients with advanced CRC gain limited benefit and face poor prognosis. Targeting the DNA damage response (DDR) in cancer cells has emerged as a promising option, yet DDR integration into clinical intervention remains under exploration. This review explains DDR inhibitor principles, summarizes current clinical status, and evaluates advancements and limitations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advances-in-dna-damage-response-inhibitors-in-colorectal-cancer-therapy/338938/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advances-in-dna-damage-response-inhibitors-in-colorectal-cancer-therapy/338938.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the rationale for using DDR inhibitors in colorectal cancer therapy?","Question",{"text":112,"@type":113},"DDR inhibitors are designed to suppress the DNA damage response in cancer cells, aiming to enhance DNA damage-based treatment effects while addressing limited benefits from existing molecular and immunotherapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the paper describe CRC development and key genomic features?",{"text":117,"@type":113},"It outlines progression from hyperplasia to adenomatous polyps and then to cancer, highlighting microsatellite instability (MSI) as a phenotypic result of deficient DNA mismatch repair.",{"name":119,"@type":110,"acceptedAnswer":120},"Which DDR inhibitor class is emphasized as having substantial research and clinical approval?",{"text":121,"@type":113},"PARP inhibitors are emphasized, with examples including olaparib, rucaparib, and niraparib, referenced as FDA-approved for management of several advanced malignancies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338938,1790141994,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Review  \nAdvances in DNA damage response inhibitors in colorectal cancer therapy  \nYue Yu†, Hang Jia†, Tianshuai Zhang†, and Wei Zhang*  \nDepartment of Colorectal Surgery, the First Affiliated Hospital, Naval Medical University, Shanghai 200433, China †These authors contributed equally to this work.  \n*Correspondence address. Tel: +86-13816321041; [E-mail:](E-mail: weizhang2000cn@163.com)[ weizhang2000cn@163.com](E-mail: weizhang2000cn@163.com)[ ](E-mail: weizhang2000cn@163.com)Received 7 February 2023 Accepted 23 August 2023  \nAbstract  \nOne potential cause of cancer is genomic instability that arises in normal cells due to years of DNA damage in the body. The clinical application of radiotherapy and cytotoxic drugs to treat cancer is based on the principle of damaging the DNA of cancer cells. However, the benefits of these treatments also have negative effects on normal tissue. While there have been notable advancements in molecular-driven therapy and immunotherapy for colorectal cancer (CRC), a considerable portion of patients with advanced CRC do not experience any benefits from these treatments, leading to a poor prognosis. In recent years, targeted therapy aimed at suppressing the DNA damage response (DDR) in cancer cells has emerged as a potential treatment option for CRC patients, offering them more choices for treatment. Currently, the integration of DDR and clinical intervention remains in the exploratory phase. This review primarily elucidates the fundamental principles of DDR inhibitors, provides an overview of their current clinical application status in CRC, and discusses the advancements as well as limitations observed in relevant studies.  \nKey words DNA damage response, colorectal cancer, targeted therapy, DDR inhibitor  \nIntroduction  \nColorectal cancer (CRC) constitutes approximately 10% of all malignancies and ranks as the second leading cause of cancerrelated mortality [1] . The pathological progression originates from hyperplasia, which subsequently progresses into benign adenomatous polyps. Over a prolonged period of time, dysplasia develops until it becomes an adenoma. Ultimately, this adenoma undergoes complete transformation into cancer and may metastasize (Figure 1) .  \nMicrosatellites are repetitive DNA sequences that exhibit higher mutation rates compared to other genomic regions. Microsatellite instability (MSI) is the phenotypic manifestation of deficient DNA mismatch repair (dMMR), which arises from mutational inactivation of genes involved in DNA mismatch repair, including MLH1, MSH2, MSH3, MSH6, and PMS2 [2] . According to MMR status, CRC can be divided into two major subtypes: microsatellite instability (MSI) and microsatellite stability (MSS) [3] .  \nThe DNA within cells is subject to daily influences from a range of internal factors and the external environment, resulting in DNA damage. Under normal circumstances, this damage can be effectively repaired through various intracellular pathways, thereby  \nensuring proper cell proliferation and apoptosis. The intracellular DNA damage response (DDR) pathway represents a sophisticated protein network system that plays a crucial role in maintaining genome integrity. Dysfunctions in the intracellular DDR have been implicated in numerous diseases including tumors, neurodegenerative disorders, and immune deficiencies [4] . The hallmark of tumor cells lies in their genomic instability, primarily characterized by alterations in chromosome number and structure, as well as MSI [5] . Therefore, DDR has emerged as a pivotal strategy for the development of anticancer drugs. Targeted inhibitors primarily exert their effects on protein kinases or selectively induce tumor cell death through synergistic lethal mechanisms. Among various DDR pathway inhibitors, poly ADP-ribose polymerase (PARP) inhibitors have garnered extensive research attention and are currently approved by the Food and Drug Administration (FDA), including olaparib, rucaparib, and niraparib, f","cbCairoTaGoxaDwK","https://ap.wps.com/l/cbCairoTaGoxaDwK","pdf",376117,"English","# Abstract\n# Introduction\n## DDR and DNA damage in CRC\n## DDR as a therapeutic strategy\n# Mechanisms of DDR in Regulating CRC\n## Proteins in DDR are the target of DDR inhibitors","[{\"question\":\"What is the rationale for using DDR inhibitors in colorectal cancer therapy?\",\"answer\":\"DDR inhibitors are designed to suppress the DNA damage response in cancer cells, aiming to enhance DNA damage-based treatment effects while addressing limited benefits from existing molecular and immunotherapies.\"},{\"question\":\"How does the paper describe CRC development and key genomic features?\",\"answer\":\"It outlines progression from hyperplasia to adenomatous polyps and then to cancer, highlighting microsatellite instability (MSI) as a phenotypic result of deficient DNA mismatch repair.\"},{\"question\":\"Which DDR inhibitor class is emphasized as having substantial research and clinical approval?\",\"answer\":\"PARP inhibitors are emphasized, with examples including olaparib, rucaparib, and niraparib, referenced as FDA-approved for management of several advanced malignancies.\"}]","Advances in DNA damage response inhibitors in colorectal cancer therapy | PDF",1790026639,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b917c6093be5b6eb44b4225200d46908.webp",983,1269,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a823a12ae7dcc388fe4221015ddf6b30.webp",982,1268,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df15de172b6922b729686df50c592af7.webp",981,1266,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ddc37b14b15866faec4b68d6b209e928.webp",980,1265]